Eli Lilly is making its biggest acquisition in years, devoting part of its GLP-1 cash influx to buy Centessa Pharmaceuticals and its experimental medicines for

Alltrna, a startup developing a new class of RNA-based drugs where a single therapy could potentially be reused across many different diseases, has received clearance

Enveda Biosciences’ first-ever clinical readout places its lead eczema drug among the top candidates in an increasingly crowded race to follow the blockbuster immunology treatment

AstraZeneca’s long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.

Blackstone has closed its latest fund – the $6.3bn BXLS VI – saying it is the largest ever private fund for the life sciences sector.